FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
- Apple (AAPL) Tops Q4 EPS by 11c; Issues Solid Outlook
- Market Wrap: IBM Profits Miss Mark; eBay Loses Noted Director; Merger Monday is Back
- After-Hours Stock Movers 10/20: (ILMN) (HLX) (AAPL) Higher; (RNO) (KALU) (UCTT) (CMG) Lower (more...)
- Chipotle Mexican Grill (CMG) Tops Q3 EPS by 31c, Offers Guidance
- AbbVie (ABBV), Shire (SHPG) Terminate Merger Talks
The FDA approved Protalix's (NYSE: PLX) Gaucher Disease drug Elelyso
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Repros Therapeutics (RPRX) Reports Not Sufficient Data for Type B pre-NDA Meeting with FDA
- ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.
- Bacterin Int'l (BONE) Launches 3Demin Cortical Fibers
Create E-mail Alert Related CategoriesFDA, Hot FDA News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!